[go: up one dir, main page]

WO2022073038A1 - Protéines de fusion à base d'interleukine-22 (il-22) et leurs utilisations - Google Patents

Protéines de fusion à base d'interleukine-22 (il-22) et leurs utilisations Download PDF

Info

Publication number
WO2022073038A1
WO2022073038A1 PCT/US2021/071686 US2021071686W WO2022073038A1 WO 2022073038 A1 WO2022073038 A1 WO 2022073038A1 US 2021071686 W US2021071686 W US 2021071686W WO 2022073038 A1 WO2022073038 A1 WO 2022073038A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
cpr01
seq
muil
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/071686
Other languages
English (en)
Inventor
Bradford L. Mcrae
Annette J. Schwartz Sterman
Soumya Mitra
Sonia TERRILLON
Valerie L. PIVORUNAS
Peter F. Bousquet
Ramkrishna SADHUKHAN
Giovanni Neri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Global Enterprises Ltd
AbbVie Inc
Original Assignee
AbbVie Global Enterprises Ltd
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Global Enterprises Ltd, AbbVie Inc filed Critical AbbVie Global Enterprises Ltd
Publication of WO2022073038A1 publication Critical patent/WO2022073038A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • Interleukin-22 is a 17 kDa globular cytokine belonging to the IL-10 family. IL-22 is mainly secreted by NK cells, dendritic cells and T-cells (Murphy (2012) Janeway’s Immunobiology Garland Science). IL-22 contains two intramolecular disulfide bonds and three N-linked glycosylation sites. IL-22 is associated with inflammatory bowel disease (IBD) susceptibility genes that are crucial for regulating tissue responses during inflammation (Mizoguchi (2012) Inflamm Bowel Dis.18:1777–1784). These processes play important roles in the pathogenesis of IBD.
  • IBD inflammatory bowel disease
  • IL22 induces mucin production, antimicrobial, proliferative and antiapoptotic pathways, which prevent tissue damage and promote epithelial repair.
  • IL-22 is associated with decreasing intestinal inflammation, targeting IL-22 to the intestine as a therapeutic presents a unique challenge.
  • fusion proteins comprising human IL-22, or a functional fragment thereof, fused to an anti-tenascin C domain D single chain variable fragment (scFv).
  • the invention provides a fusion protein comprising human interleukin-22 (hIL-22) and a single chain variable fragment (scFv) that specifically binds to human tenascin C domain D, wherein the hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the scFv comprises a heavy chain variable (VH) domain comprising the amino acid sequence set forth as SEQ ID NO: 5 and a light chain variable (VL) domain comprising the amino acid sequence set forth as SEQ ID NO: 7, and wherein the hIL-22 is conjugated to the N- terminus of the scFv via a peptide linker.
  • the peptide linker is 10 to 20 amino acids long.
  • the peptide linker comprises the amino acid sequence set forth as SEQ ID NO: 3.
  • the VH domain and the VL domain of the scFv are conjugated via a peptide linker comprising the amino acid sequence set forth as SEQ ID NO: 6.
  • the invention provides a fusion protein comprising human interleukin-22 (hIL-22) and a single chain variable fragment (scFv) that specifically binds to human tenascin C domain D, wherein the hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the scFv comprises the amino acid sequence set forth as SEQ ID NO: 4 , and wherein the hIL-22 is conjugated to the N-terminus of the scFv via a peptide linker.
  • the peptide linker comprises the amino acid sequence set forth as SEQ ID NO: 3.
  • the invention provides a fusion protein comprising human interleukin- 22 (hIL-22) and an anti- human tenascin C domain D single chain variable fragment (scFv), wherein the fusion protein comprises the amino acid sequence set forth as SEQ ID NO: 1.
  • the invention pertains to a diabody comprising two of the fusion proteins disclosed herein.
  • the invention provides a method of treating a human subject having inflammatory bowel disease (IBD), the method comprising administering a therapeutically effective dose of a fusion protein or a diabody disclosed herein, to the human subject having IBD.
  • IBD inflammatory bowel disease
  • the IBD is Crohn’s disease or ulcerative colitis.
  • the invention provides a nucleic acid encoding a fusion protein disclosed herein; a vector comprising the nucleic acid; or a host cell comprising the vector.
  • the invention provides a method of producing a fusion protein disclosed herein, the method comprising culturing a host cell comprising a vector comprising a nucleic acid encoding the fusion protein, under conditions suitable for production of the fusion protein.
  • the invention pertains to a pharmaceutical composition comprising a fusion protein disclosed herein or a diabody disclosed herein, and a pharmaceutically acceptable carrier.
  • FIG.1 is a schematic representation of the fusion protein IL-22-CPR01 containing from amino to carboxy terminus the following elements: human IL-22 (hIL-22) with a signal peptide (SP) connected via a peptide linker (L1 (GGGGS)3) to an anti-tenascin single chain variable fragment (scFv) comprising the VH and VL domains of antibody CPR01.
  • the VH and VL domains of the scFv are linked by a peptide linker (L2 GGSGG).
  • FIG.1 also describes cloning sites of the fusion protein into EcoR1 and Not1 of the pCDAN3.1 vector using primers a, b, c, d, e and f. Sequences of the primers are described in the Sequence Summary Table.
  • FIG.2 graphically depicts results of an in vitro experiment showing phosphorylation of STAT3 in human colon epithelial cell line T-84 by increasing concentrations of either human IL- 22-CPR01 (square in key) or recombinant human IL-22 protein (rhIL-22; circle in key).
  • FIGS 3A-3D provide micrographs showing the localization of mouse IL-22-CPR01 (muIL-22-CPR01; surrogate of human IL-22-CPR01) in colon tissues from a dextran sodium sulfate (DSS)-induced colitis animal model.
  • FIG.3A provides near-infrared (NIR) fluorescence image of muIL-22-CPR01 localization in colon tissues from the DSS-induced colitis model.
  • FIG. 3B provides a magnified image of the inset shown in FIG.3A.
  • FIG.3C provides a micro- autoradiography (MARG) image of muIL-22-CPR01 localization (black specks) in colon tissue of a DSS-treated mouse that was dosed with 125 I-radiolabeled muIL-22-CPR01.
  • FIG.3D provides a magnified image of the inset shown in FIG.3C.
  • FIG.4 graphically depicts results of an experiment showing protein levels (expressed as mean fluorescence intensity) of murine-IL-22-CPR01 (muIL-22-CPR01) and a non-specific antibody huIL-22 protein fusion (-huIL-22-Ab) (untargeted antibody linked to human Il-22 in the same orientation as IL-22-CPR01) in whole colon of na ⁇ ve C57/B6 mice, whole colon of 7-day DSS-treated mice, and colon lesions of 7-day DSS-treated mice that were dosed with 150 ⁇ g of 800CW-labeled huIL-22-Ab or 800CW-labeled muIL-22-CPR01.
  • muIL-22-CPR01 murine-IL-22-CPR01
  • -huIL-22-Ab non-specific antibody huIL-22 protein fusion
  • FIGS 5A-5D graphically depicts data showing the advantage offered by targeted delivery of murine IL-22-CPR01 (muIL-22-CPR01) over a control murine IL-22-Fc fusion protein (muIL- 22-Fc) in DSS-treated mice that were administered 150 ⁇ g of 800CW-labeled muIL-22-CPR01 or 800CW-labeled muIL-22-Fc on day 3 following DSS initiation.
  • Concentrations for muIL-22- CPR01 or muIL-22-Fc in whole blood or tissue (colon) homogenates were calculated by extrapolation of fluorescence intensities using calibration curves obtained with serial dilutions of the 800CW-conjugated proteins.
  • FIG.5B graphically depicts results of an experiment showing concentration of muIL-22-CPR01 or muIL-22-Fc in colon of DSS-treated mice that were dosed with 150 ⁇ g of 800CW-labeled muIL-22-CPR01 or muIL-22-Fc at 8h, 24h and 72h post-dosing.
  • FIG.5D provides representative NIR microscopy images of muIL-22-CPR01 localization in lesional regions of DSS colon tissue from DSS-treated mice that were dosed with 150 ⁇ g of 800CW-labeled muIL-22-CPR01 at 8h, 24h and 72h post-dosing.
  • FIG.6A and 6B provide representative NIR fluorescence endoscopy images showing NIR intensity map superimposed on white light images and demonstrates accumulation of muIL- 22-CPR01 in inflamed mucosa of DSS-treated undosed mice (Fig 6B) or DSS-treated mice that were dosed with 150 ⁇ g of 800CW-labeled muIL-22-CPR01 at 24h post-dosing (Fig.6A).
  • FIGS 7A-7B provide results from experiments showing prevention of epithelial erosion and suppression of inflammation in mice from a DSS-induced colitis model that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-CPR01 fusion protein (muIL- 22-CPR01) every other day beginning at the initiation of DSS.
  • PBS was used as a negative control.
  • FIG 7A graphically depicts results of an experiment showing decrease in epithelial damage (expressed as decrease in erosion length) in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-CPR01 every other day beginning at the initiation of DSS.
  • FIG 7B graphically depicts results from an experiment showing decrease in macrophage infiltration (expressed as decrease in % of IBA1) in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-CPR01 every other day beginning at the initiation of DSS.
  • PBS was used as a negative control.
  • FIGS 8A-8D provide results from experiments comparing in vivo activity of a murine IL- 22 CPR01 fusion protein (muIL-22-CPR01) ( Figures 8A and 8B) and muIL-22-Fc ( Figures 8C and 8D) in a mouse model of DSS colitis that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-CPR01 or muIL-22-Fc on days 0 and 3 beginning at the time of DSS initiation (day 0). On day 7, colons, feces and serum were collected for analyses.
  • muIL-22-CPR01 murine IL-22 CPR01 fusion protein
  • muIL-22-Fc Figures 8C and 8D
  • FIG.8A is a graph showing decrease in erosion length (circle) and increase in fecal Reg3 ⁇ (square) level in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22- CPR01 on days 0 and 3 beginning at the time of DSS initiation (day 0).
  • FIG.8B is a graph showing decrease in erosion length (circle) and unchanged serum SAA level (square) in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-CPR01 on days 0 and 3 beginning at the time of DSS initiation (day 0).
  • FIG.8C is a graph showing decrease in erosion length (circle) and increase in fecal Reg3 ⁇ level (square) in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-Fc on days 0 and 3 beginning at the time of DSS initiation (day 0).
  • FIG.8D is a graph showing decrease in erosion length (circle) and increase in serum SAA level (square) in DSS mice that were treated with increasing doses (5, 15, 50, and 150 ⁇ g/mouse) of muIL-22-Fc on days 0 and 3 beginning at the time of DSS initiation (day 0).
  • the invention relates to a fusion protein containing human IL-22 fused to a single chain variable fragment (scFv) that recognizes the D domain of human tenascin C, and use of such fusion protein, e.g., in the treatment of inflammatory bowel disease (IBD).
  • scFv single chain variable fragment
  • IBD inflammatory bowel disease
  • a fusion protein may be produced by joining two or more polynucleotides that originally coded for separate proteins into a single polynucleotide.
  • the components of the fusion protein are connected via a peptide linker.
  • domains within a fusion protein are directly fused without a linker.
  • a fusion protein comprises human IL-22 (hIL-22 or huIL-22) and an anti-tenascin C scFv where the hIL-22 and the scFv are connected via a peptide linker.
  • linker is used herein to denote an amino acid or polypeptide comprising two or more amino acid residues joined by peptide bonds, that is used to connect two or more protein moieties, e.g., two domains of a fusion protein.
  • a VH and a VL of an scFv may be connected via a linker.
  • human IL-22 and an scFv described herein may be conjugated via a linker.
  • conjugated or “linked” refers to covalent attachment or linkage of one molecule to another molecule, e.g., a cytokine, or active fragment thereof, to an scFv.
  • two polypeptides are conjugated to form a fusion protein.
  • antibody as used herein, is intended to refer to immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter- connected by disulfide bonds.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • antibody binding fragments include those that are capable of specifically binding to tenascin C, or more specifically to the D domain of tenascin C.
  • antibody binding fragments include by way of example and not limitation, Fab, Fab', F(ab') 2 , Fv fragments, and single domain fragments.
  • a Fab fragment contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.
  • Fab' fragments are produced by cleavage of the disulfide bond at the hinge cysteines of the F(ab') 2 pepsin digestion product. Additional chemical couplings of antibody fragments are known to those of ordinary skill in the art.
  • Fab and F(ab') 2 fragments lack the Fragment crystallizable (Fc) region of an intact antibody, clear more rapidly from the circulation of animals, and may have less non-specific tissue binding than an intact antibody (see, e.g., Wahl et al., 1983, J. Nucl. Med.24:316).
  • an "Fc" region is the Fragment crystallizable constant region of an antibody not comprising an antigen-specific binding region.
  • the Fc region is composed of two identical protein fragments, derived from the second and third constant domains (CH2 and CH3 domains, respectively) of the two heavy chains of an antibody.
  • IgM and IgE Fc regions contain three heavy chain constant domains (CH2, CH3, and CH4 domains) in each polypeptide chain.
  • An "Fv" fragment is the minimum fragment of an antibody that contains a complete target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (VH-VL dimer). It is in this configuration that the three CDRs of each variable domain interact to define a target binding site on the surface of the VH-VL dimer. Often, the six CDRs confer target binding specificity to the antibody.
  • variable domain or half of an Fv comprising only three CDRs specific for a target
  • Single domain fragments are composed of a single VH or VL domains which exhibit sufficient affinity to tenascin.
  • the single domain fragment is camelized (See, e.g., Riechmann, 1999, Journal of Immunological Methods 231:25-38).
  • a "single-chain Fv” or “scFv” comprises the VH and VL domains of an antibody, where these domains are present in a single polypeptide chain.
  • the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form a structure favorable for target binding.
  • the term “diabody” refers to a dimer comprising two scFv molecules that are covalently or noncovalently attached.
  • the scFv molecule may further be conjugated to another protein(s), e.g., human IL-22 or an active fragment thereof. In such an instance, a diabody would contain a dimer of a fusion protein, each containing an scFv.
  • subject refers to a human which is to be the recipient of a particular treatment.
  • terapéuticaally effective amount refers to an amount of a fusion protein effective to "treat” a disease or disorder in a human.
  • a “prophylactically effective amount” refers to an amount effective to achieve the desired prophylactic result.
  • Terms such as “treating” or “treatment” or “to treat” or “alleviating” or “to alleviate” refer to therapeutic measures that cure, slow down, lessen one or more symptoms of, and/or slow or halt progression of a diagnosed pathologic condition or disorder (“therapeutic treatment”).
  • therapeutic treatment include those already diagnosed with or suspected of having the disorder.
  • Prophylactic or preventative measures refer to measures that prevent the development of a targeted pathological condition or disorder (“prophylactic treatment”).
  • prophylactic treatment include those prone to have the disorder and those in whom the disorder is to be prevented.
  • the term "specifically binds" refers to the ability of a binding polypeptide to bind to an antigen with an Kd of at least about 1x10 -6 M, 1x10 -7 M, 1x10 -8 M, 1x10 -9 M, 1x10- 10 M, 1x10 -11 M, 1x10 -12 M, or more, and/or bind to an antigen with an affinity that is at least two- fold greater than its affinity for a nonspecific antigen.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments may be ligated.
  • viral vector Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g., non-episomal mammalian vectors
  • vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked.
  • Such vectors are referred to herein as "recombinant expression vectors” (or simply, “expression vectors”).
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably as the plasmid is the most commonly used form of vector.
  • IL-22 / Anti-Tenascin C Fusion Protein and Uses Thereof Disclosed herein are fusion proteins comprising human IL-22 conjugated to an anti- tenascin C scFv that binds to human tenascin C domain D.
  • the disclosed fusion proteins provide for localized delivery of IL-22 to a target tissue, e.g., inflamed intestinal tissue, that would benefit from IL-22 activity.
  • a fusion protein comprises an scFv comprising the variable heavy (VH) and variable light (VL) regions of the anti-tenascin C antibody CPR01 conjugated to human IL-22.
  • VH variable heavy
  • VL variable light
  • An exemplary fusion protein disclosed herein comprises the amino acid sequence set forth as SEQ ID NO: 1 in the Sequence Summary Table below. Additional details regarding human IL-22 / anti-tenascin C scFv fusion proteins are provided below.
  • IL-22 is a 17 kDa globular cytokine belonging to the IL-10 family, and is secreted by NK cells, dendritic cells and T-cells (Murphy, Janeway’s Immunobiology, Garland Science (2012)). IL-22 is also referred to as IL-10-related T-cell-derived inducible factor, TIFa, IL-21, ILTIF, IL- TIF, IL-D110, zcyto18, TIFIL-23.
  • the gene sequence of human IL-22 is described at reference sequence NCBI Gene NO. 50616, and the nucleotide mRNA reference sequence can be found at reference sequence NM_020525.5.
  • the amino acid sequence of precursor human IL-22 is provided below as SEQ ID NO: 20 (see also GenBank accession / version no. AAH70261.1): Provided herein is a fusion protein comprising human IL-22, or an active fragment thereof, where the fusion protein is designed to target IL-22 to tissue or cells that could benefit from human IL-22 activity.
  • the fusion protein comprises an active fragment of IL-22 linked to an anti-tenascin C domain D scFv, e.g., scFv comprising the amino acid sequence set forth as SEQ ID NO: 4.
  • the fusion protein of the invention comprises human IL-22 comprising the amino acid sequence of SEQ ID NO: 2.
  • fusion proteins comprising active fragments of SEQ ID NO: 20
  • Active fragments of human IL-22 can be identified according to standard methods known in the art where the active fragment retains one or more biological activities associated with human IL-22.
  • human IL-22 activates intracellular kinase JAK which in turn induces phosphorylation of STAT3.
  • an active fragment of human IL-22 can be identified as a fragment that is able to induce phosphorylation of STAT3 in an in vitro assay.
  • An example of such an assay is provided in Example 2 using T-84 human colon epithelial cells.
  • a fusion protein of the invention comprises human IL-22 comprising SEQ ID: 2 or 20, or an active fragment thereof, comprising at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to either SEQ ID NO: 20 or 2.
  • fusion proteins comprising human IL-22 comprising the amino acid sequence set forth as SEQ ID NO: 2, or an active fragment thereof, where the amino acid sequence contains conservative amino acid substitutions that do not substantially impact the activity of human IL-22, or the fragment thereof. Activities of human IL-22 that can be tested are described above in the context of fragments and are also relevant to testing variants of IL- 22.
  • Conservative amino acid substitutions may be defined by substitutions within the classes of amino acids, i.e., acidic residues Asp (D) and Glu (E); basic residues Lys (K), Arg (R), and His (H); hydrophilic uncharged residues Ser (S), Thr (T), Asn (N), and Gln (Q); aliphatic uncharged residues Gly (G), Ala (A), Val (V), Leu (L), and Ile (I); non-polar uncharged residues Cys (C), Met (M), and Pro (P); and aromatic residues Phe (F), Tyr (Y), and Trp (W).
  • acidic residues Asp (D) and Glu (E) basic residues Lys (K), Arg (R), and His (H); hydrophilic uncharged residues Ser (S), Thr (T), Asn (N), and Gln (Q); aliphatic uncharged residues Gly (G), Ala (A), Val (V), Leu (L), and
  • a fusion protein of the invention comprises human IL-22, or an active fragment thereof, having at least 10, such as 9, 8, 7, 6, 5, 4, 3, 2 or 1, conservative amino acid residue replacements, e.g., 9, 8, 7, 6, 5, 4, 3, 2 or 1, conservative amino acid residue substitutions within SEQ ID NO: 2.
  • targeted delivery of human IL-22 is achieved by conjugating human IL-22, or an active fragment thereof, to an antibody, or an antigen binding fragment thereof, that binds to human tenascin C, specifically the D domain of human tenascin C.
  • human IL-22 By conjugating human IL-22 to an anti-tenascin C (D domain of tenascin C) antibody or an antigen-binding fragment thereof, human IL-22 is directed to tissues expressing the D domain of tenascin C.
  • Tenascin C modulates cellular adhesion and is a large hexameric glycoprotein of the extracellular matrix.
  • Tenascin C is involved in cell proliferation and cell migration and is associated with changes in tissue architecture as occurring during morphogenesis and embryogenesis as well as under tumorigenesis or angiogenesis.
  • a fusion protein disclosed herein comprises an anti-tenascin C antibody or a fragment thereof (e.g., an antigen-binding fragment thereof) that specifically binds to the D domain of tenascin C, conjugated to human IL-22, or an active fragment thereof.
  • the anti-tenascin C antibody, or antigen-binding fragment thereof is CPR01, or an antigen binding fragment of CPR01.
  • CPR01 and CPR01 variants are described, for example, in WO 2017/097990 and US Patent No. 10,647,760, the contents of which are incorporated herein by reference in its entirety.
  • CPR01 cross reacts with the D domain of murine and human tenascin C.
  • the amino acid sequence of the variable heavy (VH) chain region of CPR01 is as set forth as SEQ ID NO: 5
  • the amino acid sequence of the variable light chain region of CPR01 is as set forth as SEQ ID NO: 7.
  • an anti-tenascin C scFv for use in the compositions and methods described herein may comprise the variable heavy and light chains of antibody CPR01, i.e., the amino acid sequences set forth as SEQ ID NOs: 5 and 7, respectively.
  • a fusion protein comprises human IL-22, or an active fragment thereof, conjugated to an anti-tenascin C scFv comprising a variable heavy chain region comprising an amino acid sequence set forth as SEQ ID NO: 5 and a variable light chain region comprising an amino acid sequence set forth as SEQ ID NO: 7.
  • the fusion protein comprises human IL-22, or an active fragment thereof, conjugated to an anti-tenascin C scFv comprising a heavy chain variable region comprising a CDR1 domain as set forth as amino acid residues 26-35 of SEQ ID NO: 5, a CDR2 domain as set forth as amino acid residues 50-66 of SEQ ID: 5, and a CDR3 domain as set forth as amino acid residues 99-105 of SEQ ID NO: 5; and a light chain variable region comprising a light chain variable region comprising a light chain variable region comprising a CDR1 domain as set forth as amino acid residues 23-33 of SEQ ID NO: 7, a CDR2 domain as set forth as amino acid residues 49-55 of SEQ ID: 7, and a CDR3 domain as set forth as amino acid residues 88-98 of SEQ ID NO: 7.
  • a fusion protein comprises human IL-22, or an active fragment thereof, conjugated to an anti-tenascin C scFv comprising the amino acid sequence set forth as SEQ ID NO: 4.
  • the fusion protein comprises human IL- 22, or an active fragment thereof, conjugated to an anti-tenascin C antibody, or an antigen- binding fragment thereof, comprising a heavy chain variable region comprising a heavy chain CDR set as set forth as SEQ ID NO: 5, and a light chain variable region comprising a light chain CDR set as described as SEQ ID NO: 7.
  • the fusion protein comprises human IL-22, or an active fragment thereof, conjugated to an anti-tenascin C antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region comprising a CDR1 domain as set forth as amino acid residues 26-35 of SEQ ID NO: 5, a CDR2 domain as set forth as amino acid residues 50-66 of SEQ ID: 5, and a CDR3 domain as set forth as amino acid residues 99-105 of SEQ ID NO: 5; and a light chain variable region comprising a light chain variable region comprising a CDR1 domain as set forth as amino acid residues 23-33 of SEQ ID NO: 7, a CDR2 domain as set forth as amino acid residues 49-55 of SEQ ID: 7, and a CDR3 domain as set forth as amino acid residues 88-98 of SEQ ID NO: 7
  • a fusion protein disclosed herein comprises human IL-22, or an active fragment thereof, and an anti-tenascin
  • a fusion protein disclosed herein comprises human IL-22, or an active fragment thereof, and an anti-tenascin C antibody, an antigen-binding fragment thereof, or an scFv, comprising a VL region having the CDRs set forth as SEQ ID NO: 7 and having at least 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 7 other than the CDRs.
  • sequence identity may be determined using methods known in the art. For example, sequence identity of two sequences may be determined using the algorithm GAP (Wisconsin GCG package, Accelerys Inc, San Diego USA).
  • BLAST which uses the method of Altschul et al., J Mol Biol 215: 405-410 (1990)
  • FASTA which uses the method of Pearson and Lipman, PNAS USA 85:2444- 2448 (1988)
  • an anti-tenascin C antibody, an antigen- binding fragment thereof, or an scFv comprises a heavy chain and/or a light chain variable region set forth as SEQ ID NOs: 5 and 7, respectively, where the heavy and/or light chain contains conservative amino acid substitutions.
  • conservative amino acid substitutions may be defined by substitutions within the classes of amino acids.
  • a fusion protein of the invention comprises an anti-tenascin C scFv comprising a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 5 and having at least 10, such as at least 9, 8, 7, 6, 5, 4, 3, 2 or 1, conservative amino acid residue substitutions, and comprising a variable light chain region comprising the amino acid sequence set forth as SEQ ID NO: 7 and having 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1, conservative amino acid residue substitutions.
  • a fusion protein of the invention comprises an anti-tenascin C scFv comprising the amino acid sequence set forth as SEQ ID NO: 4, and having 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1, conservative amino acid residue substitutions.
  • an anti-tenascin scFv included in the fusion protein of the disclosure comprises a heavy chain variable region and a light chain variable region that are connected by a linker.
  • an anti-tenascin C scFv e.g., scFv-CPR01
  • an anti-tenascin C scFv included in the fusion protein of the invention comprises a VH domain comprising the amino acid sequence set forth as SEQ ID NO: 5 and a VL domain comprising the amino acid sequence set forth as SEQ ID NO: 7, where the VH and VL domains are linked by a peptide linker.
  • the length of the peptide linker between the VH and VL chains is less than 15 amino acids, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acids.
  • the peptide linker contains 5- 12, 5-11, 6-12, 7-12, 4-10 amino acids, 4-9 amino acids, or 4-8 amino acids.
  • the peptide linker comprises the amino acid sequence GGSGG (SEQ ID NO: 6).
  • the present disclosure provides a fusion protein comprising an anti-tenascin C domain D antibody, an antigen-binding fragment thereof, or an scFv conjugated to human IL-22, or an active fragment of human IL-22.
  • the anti-tenascin antibody, fragment, or scFv, and human IL-22, or fragment thereof may be conjugated via a linker.
  • an anti-tenascin C domain D scFv and human IL-22, or an active fragment thereof are conjugated via a peptide linker.
  • the peptide linker comprises 10-20 amino acids, 11-19 amino acids, 12-18 amino acids, 13-17 amino acids, 19 amino acids, 18 amino acids, 17 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, and so forth.
  • an anti-tenascin C scFv and human IL-22, or an active fragment thereof are conjugated via a peptide linker comprising the amino acid sequence (GGGGS) 3 (SEQ ID NO: 3).
  • a fusion protein of the disclosure comprises human IL-22, or an active fragment thereof, conjugated either through a peptide linker or directly, to the N-terminus of an anti-tenascin C scFv. Such an orientation is described in Figure 1.
  • human IL-22, or an active fragment thereof is conjugated to the C terminus of an anti-tenascin C scFv.
  • human IL-22 is conjugated, either through a peptide linker or directly without a linker, via its C-terminus or N-terminus to an anti-tenascin C domain D antibody molecule to form a targeted fusion protein.
  • human IL-22 (or an active fragment thereof) is conjugated to an scFv, that binds human tenascin C domain D via the C-terminus of huIL-22 (or an active fragment thereof).
  • huIL-22 (or an active fragment thereof) is connected via its C-terminus to an scFv comprising an amino acid sequence set forth as SEQ ID NO: 4.
  • a fusion protein comprises an active fragment of human IL-22 as set forth as SEQ ID NO: 2 conjugated via a peptide linker (e.g., SEQ ID NO: 3) to the amino terminus of an anti-tenascin C scFv comprising a heavy chain variable region (VH) comprising an amino acid sequence set forth as SEQ ID NO: 5 and a light chain variable region (VL) comprising the amino acid sequence set forth as SEQ ID NO: 7.
  • VH heavy chain variable region
  • VL light chain variable region
  • the VH and the VL are connected via a peptide linker that is 10-20 amino acids in length.
  • a fusion protein comprises an active fragment of human IL-22 as set forth as SEQ ID NO: 2 conjugated via a peptide linker to the amino terminus of an anti-tenascin C scFv comprising the amino acid sequence set forth as SEQ ID NO: 4.
  • the peptide linker connecting the anti-tenascin scFv and human IL-22, or an active fragment thereof comprises the amino acid sequence set forth as SEQ ID NO: 3.
  • a fusion protein described herein comprises human interleukin- 22 (hIL-22) and an scFv that specifically binds to human tenascin C domain D, wherein hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2, and wherein the scFv comprises a heavy chain variable (VH) domain comprising the amino acid sequence set forth as SEQ ID NO: 5 and a light chain variable (VL) domain comprising the amino acid sequence set forth as SEQ ID NO: 7, and wherein the hIL-22 is conjugated to the N-terminus of the scFv via a peptide linker.
  • hIL-22 human interleukin- 22
  • scFv that specifically binds to human tenascin C domain D
  • hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2
  • the scFv comprises a heavy chain variable (VH) domain comprising the amino acid sequence set forth as SEQ ID NO: 5 and a light chain
  • a fusion protein of the invention comprises human interleukin-22 (hIL-22) and an scFv that specifically binds to human tenascin C domain D, wherein the hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the scFv comprises the amino acid sequence set forth as SEQ ID NO: 4 , and wherein the hIL-22 is conjugated to the N-terminus of the scFv via a peptide linker.
  • hIL-22 human interleukin-22
  • scFv that specifically binds to human tenascin C domain D
  • the hIL-22 comprises the amino acid sequence set forth as SEQ ID NO: 2
  • the scFv comprises the amino acid sequence set forth as SEQ ID NO: 4
  • the hIL-22 is conjugated to the N-terminus of the scFv via a peptide linker.
  • a fusion protein comprises human interleukin-22 (hIL-22) and an scFv that specifically binds to human tenascin C domain D, wherein the fusion protein comprises the amino acid sequence set forth as SEQ ID NO: 1.
  • fusion proteins described herein are described in the context of a monomer, i.e., a single chain protein comprising human IL-22 (huIL-22) or an active fragment thereof (e.g., SEQ ID NO: 2) conjugated to an anti-tenascin C domain D scFv (e.g., scFv comprising the amino acid sequence set forth as SEQ ID NO: 4) via a linker
  • a monomers form diabodies in solution
  • fusion proteins described herein form diabodies comprising two fusion proteins that associate via their respective scFv regions. This association is non-covalent.
  • diabodies comprising fusion proteins described herein are also contemplated in the invention.
  • a diabody comprises two fusion proteins that are non- covalently associated, wherein each of the fusion proteins comprises the amino acid sequence set forth as SEQ ID NO: 1.
  • a diabody comprises two fusion proteins that are non-covalently associated, where each of the fusion proteins comprises an human IL-22 (huIL-22) or an active fragment thereof (e.g.,the amino acid sequence set forth as SEQ ID NO: 2) conjugated to an anti-tenascin C domain D scFv (e.g., scFv comprising the amino acid sequence set forth as SEQ ID NO: 4), where the carboxy terminus of the huIL-22 is conjugated via a linker to the amino terminus of the scFv.
  • the disclosure provides a solution comprising a diabody disclosed herein.
  • the solution is characterized as a solution in which fusion proteins of the invention can form diabodies, including, for example, phosphate buffered saline (PBS).
  • Fusion proteins of the disclosure may be produced using nucleic acid molecules corresponding to the amino acid sequences disclosed herein.
  • nucleic acid molecules comprising nucleic acid sequences set forth as SEQ ID NOs: 14, 15, 16, 17, 18, or 19, or combinations thereof, are used in the production of a fusion protein.
  • constructs in the form of plasmids, vectors (e.g., expression vectors), transcription or expression cassettes which comprise such nucleic acids.
  • Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate.
  • Vectors may be plasmids e.g., phagemid, or viral e.g., phage, as appropriate.
  • plasmids e.g., phagemid, or viral e.g., phage, as appropriate.
  • nucleic acid molecules comprising polynucleotide sequences described in the Sequence Summary Table are also included in the invention. Such vectors can be introduced into an appropriate host cell for expression. Fusion proteins may be produced by any of a number of techniques.
  • expression from host cells wherein expression vector(s) encoding the fusion protein is (are) transfected into a host cell by standard techniques.
  • transfection are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE- dextran transfection and the like.
  • Preferred host cells for expressing the fusion proteins of the invention include mammalian cells.
  • the fusion proteins are produced by culturing the host cells for a period of time sufficient to allow for expression of the fusion protein in the host cells or, more preferably, secretion of the fusion protein into the culture medium in which the host cells are grown.
  • Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium.
  • the selected transformant host cells are cultured to allow for expression of the fusion protein and fusion protein is recovered from the culture medium.
  • a fusion protein of the invention may be purified or isolated by methods known in the art in that it is identified and separated and/or recovered from its natural environment and separated from contaminants that would interfere with diagnostic or therapeutic uses for the fusion protein. These isolated preparations may be purified using various art-recognized techniques. Fusion proteins described herein may be used for therapeutic purposes, including for the treatment of inflammatory bowel disease (IBD). Fusion proteins of the present disclosure can thus be used in treatment of IBD in patients, preferably human patients. Examples of IBD that can be treated using the fusion proteins described herein include Crohn’s Disease (CD) and ulcerative colitis (UC).
  • IBD inflammatory bowel disease
  • CD Crohn’s Disease
  • UC ulcerative colitis
  • a human subject having IBD is treated by administering to a patient suffering from IBD a therapeutically effective amount of a fusion protein of the present disclosure.
  • compositions provided herein may be administered to mammals, preferably humans. Administration may be in a therapeutically effective amount, which is an amount sufficient to show benefit to a patient (e.g., an IBD patient (e.g., CD patient, UC patient, etc.)). Such benefit may be at least amelioration of at least one symptom (e.g., at least one symptom of IBD (e.g., CD, UC, etc.)).
  • Fusion proteins and diabodies according to the present disclosure can be administered in the form of a pharmaceutical composition, which may contain at least one pharmaceutically acceptable excipient and/or carrier in addition to the fusion protein or diabody. Further aspects and embodiments of the disclosure will be apparent to those skilled in the art given the present disclosure including the following experimental exemplification. EXAMPLES The following Examples may be used for illustrative purposes and should not be deemed to narrow the scope of the invention.
  • Example 1. Cloning and expression of IL-22 anti-tenascin C scFv fusion protein The following example describes the cloning and expression of a fusion protein (referred to as IL-22-CPR01) that contains human IL-22 fused to the N-terminus of scFv-CPR01.
  • CPR01 is an antibody that binds to the D domain of human tenascin C (see WO 2017/097990).
  • the amino acid sequence of IL-22-CPR01 is set forth as SEQ ID NO: 1.
  • SEQ ID NO: 1 As described in SEQ ID NO: 1 below, a 15 amino acid peptide linker (L1:(GGGGS)3) (SEQ ID NO: 3) (shown in bold) links the cytokine IL-22 (italicized in SEQ ID NO: 1) with scFv-CPR01.
  • the VH and VL domains of scFv-CPR01 are linked by a short 5 amino acid peptide linker (L2:(GGSGG) (SEQ ID NO: 6) (underlined below).
  • FIG. 1 A cloning map and orientation of IL-22-CPR01 is shown in Figure 1, which describes a signal peptide (SP) fused to the amino terminus of human IL-22 protein. Cloning of IL-22-CPR01 was performed by standard molecular biology techniques using primers a, b, c, d, e, and f (SEQ ID NOs 8 to 13, respectively), as described in Figure 1. The IL- 22-CPR01 nucleic acid sequence within the plasmid was confirmed by Sanger sequencing.
  • SP signal peptide
  • IL-22-CPR01 induces STAT3 phosphorylation in vitro IL-22 signal transduction involves the activation of JAK, which subsequently induces phosphorylation of STAT3.
  • the ability of IL-22-CPR01 to induce STAT3 phosphorylation was assessed in order to evaluate the bioactivity of IL-22-CPR01.
  • T-84 cells human colon epithelial cell line
  • DMEM/F12 Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12
  • FBS Fetal Bovine Serum
  • rhIL-22 increased STAT3 phosphorylation with an average EC50 value of 0.042 ⁇ 0.008 nM (experiment was performed three times).
  • IL-22-CPR01 exhibited bioactivity, demonstrated by its ability to induce STAT3 phosphorylation in an in vitro STAT3 phosphorylation assay.
  • Example 3 In vivo imaging shows muIL-22-CPR01 localization to gut tissue
  • CPR01-muIL-22 surrogate molecule CPR01-murine IL-22
  • Imaging analysis was performed using both IL-22-CPR01 and its murine surrogate muIL-22- CPR01(murine IL-22 fused to CPR01 scFv).
  • Materials and methods Near infrared labeling of muIL-22-CPR01 Fluorescently labeled CPR01 fusion proteins containing murine IL-22 (muIL-22) were generated using heterogeneous lysine labeling. 1 mg of fusion protein in 500 ⁇ l PBS was labeled with 5 nmol of 800CW NHS ester (929-70020, LICOR) according to the following protocol.
  • the fusion protein was thawed at 4°C and desalted 2x using ZEBA 7kDa MWCO (5 ml size) desalting columns following manufacturer’s instructions. Desalting columns were washed using PBS. Post desalting, A280 for the protein was collected to account for potential protein loss. Based on A280, the amount of 800CW NHS ester for the reaction was determined in accordance to a 1:0.8 protein:fluorophore stoichiometric ratio. To a solution of desalted protein, 10% V/V of 7.5% sodium bicarbonate buffer was added, followed by 800CW NHS ester in a sterile polypropylene EPPENDORF tube.
  • In vivo targeting in colitis mouse model In vivo targeting performance of muIL-22-CPR01 was assessed by quantitative bio- distribution studies in a dextran sodium sulfate (DSS)-induced colitis model. As described above, muIL-22-CPR01 was used as a surrogate to CPR01-huIL-22 in the murine colitis model. Acute murine colitis was induced in C57BL/6 mice with 3% DSS in drinking water, and on day 7, 150 ⁇ g of 800CW-labeled muIL-22-CPR01 was administered intravenously (i.v.) via the tail vein.
  • DSS dextran sodium sulfate
  • mice were sacrificed 24 h post-injection, perfused with saline and the organs were excised to acquire fluorescence images across different tissues using a LICOR Pearl imaging system. The organs were then weighed and homogenized, and the fluorescence intensities measured on a LICOR Odyssey CLx plate scanner were converted to concentrations using a standard curve created with the dosing solution.
  • a cohort of DSS mice were dosed and perfused as described above, and colons from these mice were resected and flushed thoroughly with saline to remove residual fecal material, followed by fixation in 4% paraformaldehyde for 24 h.
  • tissues were placed in 30% cold sucrose for 24 h at 4°C.
  • the samples were then positioned in molds containing OCT (TISSUE TEK embedding medium, SAKURA, Cat #4583) and frozen by slowly immersing the mold in cold 2-methylbutane (JT BAKER; Cat #Q223-08) chilled in dry ice bucket.
  • Frozen blocks were then stored at -80 ⁇ C.
  • Colon sections (10 ⁇ m) were cut using a cryostat and mounted on a glass slide, following which the slides were incubated in 1 ⁇ g/mL Hoechst nuclear stain for 10 min.
  • Figure 3A provides an NIR fluorescent image of DSS colon illustrating focal distribution of muIL-22-CPR01, as described in Figure 3A (see, e.g., box region), while Figure 3B provides an NIR fluorescent microscopy image of a colon tissue section indicating that the NIR fluorescence signal originated from an inflamed region of the colon.
  • mice were dosed 150 ⁇ g of either 800CW-labeled surrogate muIL-22-CPR01 or labeled muIL-22-Fc (see Example 3 for protocol). ⁇ Blood samples were obtained at multiple time-points post-dosing up to 72 hours (h), and the 800CW fluorescence signal was converted to whole blood concentration by comparing the intensity to a calibration curve of known concentrations. The whole blood PK profile was then fitted to a biexponential decay using PRISM. As described in Figure 5A, muIL-22-CPR01 showed a faster decay or a shorter circulation half-life compared to muIL-22-Fc.
  • Concentration of muIL-22-CPR01 in tissue homogenates was calculated by extrapolation of fluorescence intensities using calibration curves obtained with serial dilutions of the 800CW-conjugated proteins.
  • concentration of muIL-22-CPR01 in the colon was higher than that of muIL-22-Fc at both 8 hours and 24 hours post-dosing.
  • the decreased concentration of muIL-22-CPR01 at 72 hours post-dosing was consistent with its shorter half-life compared to muIL-22-Fc.
  • the colon:blood ratio of muIL-22-CPR01 and muIL-22-Fc was also calculated. As described in Figure 5C, muIL-22-CPR01 exhibited a higher colon:blood ratio at 24 hours and 72 hours post-dosing compared to muIL-22-Fc. The higher colon:blood ratio of muIL-22-CPR01 at 24 hours and 72 hours shows the benefit of targeted delivery offered by the diabody format of a IL-22-CPR01 fusion protein even with its the shorter circulation half-life compared to that of IL- 22-Fc. NIR microscopy images of DSS colon tissue were obtained at 24 hours, 48 hours, and 72 hours following dosing with 800CW-labeled CPR01-muIL-22; the images are provided in Figure 5D.
  • Example 6 In vivo efficacy of muIL-22-CPR01 in colitis model The following study was conducted to evaluate the in vivo efficacy of IL-22-CPR01 (via surrogate) in a mammalian disease model for inflammatory bowel disease (IBD). Materials and methods On Day 0, 3% DSS dissolved in water was provided in 500 ml bottles ad libitum to female C57Bl/6N mice (6-8 wks, 5 per cage).
  • the SDD measurement starts at the rectal mucosal junction and continues along the inflamed colon proximally until glands recover to a point greater than 50% of the mucosal surface.
  • Erosions were measured from the rectum proximally in both colon segments. Erosions were defined as loss of surface epithelium and were measured on either side of the lumen up to 3 cm proximal from the rectum.
  • length measurements in microns were drawn on the image and exported to a spreadsheet for analysis. Line measurements started at the rectal mucosal junction and continued along the colon to a point of about 3 cm. Image analysis of the macrophage marker IBA-1 was used as a quantitative endpoint of mucosal inflammation.
  • IHC immunohistochemical evaluation of IBA-1
  • 5 ⁇ m sections from paraffin embedded tissues were prepared. IHC staining for IBA-1 was performed using the LEICA BOND RX automated stainer (LEICA BIOSYSTEMS). Sections were deparaffinized, and antigens were retrieved with proprietary buffer, ED2 (EDTA buffer, LEICA BIOSYSTEMS). Sections were incubated with primary antibody for IBA-1 (Rabbit Polyclonal, WAKO, Cat # 019- 19741) at 0.15 ⁇ g/ml in PBS; optimized concentration of the primary antibody was previously determined on control tissues. Next, a proprietary goat anti-rabbit HRP polymer (LEICA BIOSYSTEMS) was applied to sections followed by a peroxidase blocking reagent.
  • LICA BIOSYSTEMS proprietary goat anti-rabbit HRP polymer
  • the detection was performed with the LEICA DAB kit (LEICA BIOSYSTEMS) and slides were counterstained with hematoxylin.
  • IBA-1 image analysis was performed using Visiopharm. Prior to analysis, a region of interest (ROI) around the distal colon was circled. The tertiary lymphoid organs (TLO) external to the muscularis mucosa and the rectum were removed from this ROI.
  • VISIOPHARM software was used to run two algorithms for the complete analysis: Step (1) algorithm to identify mucosa versus submucosa and muscularis; and step (2) algorithm to identify 3,3’-diaminobenzidine (DAB)+ IBA-1+ macrophages in that area.
  • DAB 3,3’-diaminobenzidine
  • muIL-22-CPR01 was administered intravenously every other day beginning at the initiation of DSS and inhibited development of erosions in acute DSS-induced colitis in a range of doses, as described in Figure 7A. For example, at a dose of 150 ⁇ g close to 80% inhibition of erosions was observed. muIL-22-CPR01 also inhibited influx of macrophages into the lamina intestinal, as described in Figure 7B. This effect was secondary to improving epithelial barrier function as macrophages do not express IL-22R. This data indicates that IL-22-CPR01 is effective in preventing epithelial damage associated with colitis, thereby, decreasing inflammatory cell burden in the lamina limbal.
  • Example 7 Comparison study of IL-22-CPR01 vs.
  • IL-22-Fc A study was performed to compare the activity of IL-22-CPR01 (via surrogate muIL-22- CPR01) to muIL-22-Fc. In vivo studies were performed using the murine DSS colitis model. Mice were treated with a dose response (150, 50, 15 and 5 ⁇ g/mouse) of muIL-22- CPR01 or muIL-22-Fc on days 0 and 3 beginning at the time of DSS initiation (day 0). On day 7, colons, feces and serum were collected for analyses.
  • Efficacy was determined by the effect of drug (muIL-22-CPR01 or muIL-22-Fc) treatment on epithelial erosions in the colon.
  • the results form the study are shown in Figures 8A and 8C.
  • muIL-22-CPR01 decreased erosion lengths and induced expression of fecal Reg3 ⁇ in a range of doses, suggesting that Reg3 expression correlated with therapeutic response in this model.
  • treatment with muIL-22-Fc also showed a dose-responsive effect on epithelial damage and erosion length and increased fecal Reg3 ⁇ levels (Figure 8C).
  • muIL-22-Fc Treatment with muIL-22-Fc also showed a dose-responsive effect on epithelial damage and erosion length and increased fecal Reg3 ⁇ levels ( Figures 8C and 8D).
  • the magnitude of Reg3 ⁇ induction was greater with IL-22-Fc treatment vs. muIL-22-CPR01 potentially due to the fact that muIL-22-Fc is not targeted to inflamed sites but stimulates Reg3 ⁇ production throughout the colon.
  • muIL-22-Fc produced a dose responsive increase in serum SAA consistent with the longer serum half-life for this drug and the reported systemic bioactivity of muIL-22-Fc ( Figures 8C and 8D).
  • muIL-22-CPR01 is efficacious in mouse DSS, exhibits local bioactivity, and demonstrates a benefit over muIL-22-Fc by sparing extra-intestinal bioactivity as measured by serum SAA.
  • the observation that both IL-22-CPR01 and muIL-22-Fc induce fecal Reg3 ⁇ , but only muIL-22-Fc induces serum SAA points to the fact that muIL-22-CPR01 may have tissue-specific biological responses that can be harnessed to monitor gut versus extra-intestinal IL-22 activity directly in the serum.
  • the data described in Figures 7A-7B and 8A-8D support a finding that IL- 22-CPR01 can inhibit epithelial erosion and suppress inflammation in IBD using a murine colitis model. Sequences disclosed herein and/or relevant to the present invention are listed in the Sequence Summary Table.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéine de fusion comprenant de l'IL-22 humaine, ou un fragment actif de celle-ci, conjuguée à un scFv d'anti-ténascine, ainsi que des utilisations correspondantes.
PCT/US2021/071686 2020-10-02 2021-10-01 Protéines de fusion à base d'interleukine-22 (il-22) et leurs utilisations Ceased WO2022073038A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086967P 2020-10-02 2020-10-02
US63/086,967 2020-10-02

Publications (1)

Publication Number Publication Date
WO2022073038A1 true WO2022073038A1 (fr) 2022-04-07

Family

ID=78599270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/071686 Ceased WO2022073038A1 (fr) 2020-10-02 2021-10-01 Protéines de fusion à base d'interleukine-22 (il-22) et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2022073038A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050834A2 (fr) 2004-11-09 2006-05-18 Philogen Spa Anticorps vis-a-vis de la tenascine-c
WO2017009469A1 (fr) * 2015-07-16 2017-01-19 Philogen S.P.A. Immunoconjugués d'il22
WO2017097990A1 (fr) 2015-12-11 2017-06-15 Philogen S.P.A. Anticorps pour le traitement et le diagnostic d'une maladie intestinale inflammatoire
WO2019148026A1 (fr) * 2018-01-26 2019-08-01 Genentech, Inc. Protéines de fusion il-22 fc et procédés d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050834A2 (fr) 2004-11-09 2006-05-18 Philogen Spa Anticorps vis-a-vis de la tenascine-c
WO2017009469A1 (fr) * 2015-07-16 2017-01-19 Philogen S.P.A. Immunoconjugués d'il22
WO2017097990A1 (fr) 2015-12-11 2017-06-15 Philogen S.P.A. Anticorps pour le traitement et le diagnostic d'une maladie intestinale inflammatoire
US10647760B2 (en) 2015-12-11 2020-05-12 Philogen S.P.A. Antibodies for treatment and diagnosis of inflammatory bowel disease
WO2019148026A1 (fr) * 2018-01-26 2019-08-01 Genentech, Inc. Protéines de fusion il-22 fc et procédés d'utilisation

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. AAH70261.1
"NCBI", Database accession no. 50616
"Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", 1999, JOHN WILEY & SONS
ALTSCHUL ET AL., J MOL BIOL, vol. 215, 1990, pages 405 - 410
BOOTZ FRANZISKA ET AL: "Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 1, 23 October 2015 (2015-10-23), pages 180 - 189, XP029388945, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2015.10.012 *
BORSI ET AL., INT J CANCER, vol. 52, 1992, pages 688 - 692
CARNEMOLLA ET AL., EUR J BIOCHEM, vol. 205, 1992, pages 561 - 567
ECKHARDT, BMC GASTROENTEROL, vol. 10, 2010, pages 133
FRANZISKA BOOTZ ET AL: "Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 22, no. 9, 1 September 2016 (2016-09-01), US, pages 2098 - 2105, XP055307423, ISSN: 1078-0998, DOI: 10.1097/MIB.0000000000000851 *
LI ET AL., WORLD J GASTROENTEL, vol. 20, no. 48, 2014, pages 18177 - 18188
MIZOGUCHI ATSUSHI ET AL: "Clinical importance of IL-22 cascade in IBD", JOURNAL OF GASTROENTERLOGY, SPRINGER JAPAN KK, JP, vol. 53, no. 4, 26 October 2017 (2017-10-26), pages 465 - 474, XP036465929, ISSN: 0944-1174, [retrieved on 20171026], DOI: 10.1007/S00535-017-1401-7 *
MIZOGUCHI, INFFAMM BOWEL DIS, vol. 18, 2012, pages 1777 - 1784
MURPHY: "Janeway s Immunobiology", 2012, GARLAND SCIENCE
NUCL ACIDS RES, vol. 25, 1997, pages 3389 - 3402
PEARSONLIPMAN, PNAS USA, vol. 85, 1988, pages 2444 - 2448
RIECHMANN, JOURNAL OF IMMUNOLOGICAL METHODS, vol. 231, 1999, pages 25 - 38
ROTHENBERG, CLIN PHARMACOL THER, vol. 105, 2019, pages 177 - 189
SAMBROOKRUSSELL: "Molecular Cloning: a Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SMITHWATERMAN, J MOL BIOL, vol. 147, 1981, pages 195 - 197
WAHL, J. NUCL. MED., vol. 24, 1983, pages 316
ZHANG LIANG ET AL: "Imaging the Alternatively Spliced D Domain of Tenascin C in Preclinical Models of Inammatory Bowel Disease", 20 October 2021 (2021-10-20), pages 1 - 20, XP055877463, Retrieved from the Internet <URL:https://www.researchgate.net/publication/355462495_Imaging_the_Alternatively_Spliced_D_Domain_of_Tenascin_C_in_Preclinical_Models_of_Inflammatory_Bowel_Disease/fulltext/617638dd3c987366c3e26a84/Imaging-the-Alternatively-Spliced-D-Domain-of-Tenascin-C-in-Preclinical-Models-of-Inflammatory-Bowel-Disea> [retrieved on 20220111], DOI: 10.21203/rs.3.rs-984872/v1 *

Similar Documents

Publication Publication Date Title
JP6495884B2 (ja) 改変抗ｔｇｆベータ抗体および抗原結合フラグメント
US20110009337A1 (en) Q3 sparc deletion mutant and uses thereof
JP2010529859A (ja) ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
KR20140059168A (ko) 시신경 척수염 치료용 조성물 및 치료 방법
CN120919282A (zh) 用于治疗肺高压的组合物和方法
CA2664327A1 (fr) Methode de detection et de traitement de troubles cutanes
WO2018199318A1 (fr) Anticorps anti-gpc-1
US10172918B2 (en) SorCS1 for the treatment of obesity
JP2002516572A (ja) 組織の再生の調節
CN113735974B (zh) 针对Claudin18.2的抗体及其用途
JP2018529729A (ja) 胆汁酸障害の処置
KR20230156798A (ko) 전환 성장 인자-β1에 높은 친화성, 결합력 및 특이성으로 결합하는 ｓｃＦｖ-Ｆｃ 이량체
WO2022073038A1 (fr) Protéines de fusion à base d&#39;interleukine-22 (il-22) et leurs utilisations
US11124574B2 (en) Specific photoimmuno-theranostics for detection and elimination of skin cancer cells
JP2007534305A (ja) サル免疫グロブリン配列
BR112021013571A2 (pt) Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
KR20210025063A (ko) 항-마리노부파게닌 항체 및 이의 용도
WO2024014463A1 (fr) Agent pour traiter ou prévenir des calculs rénaux
WO2017050955A1 (fr) Polypeptides pouvant inhiber la liaison entre la leptine et le vegf165
KR101836756B1 (ko) Il-17a를 표적화하는 백신
EP4663202A1 (fr) Préparation pharmaceutique contenant une protéine de liaison bispécifique anti-vegfa et anti-vegfc
DK2953975T3 (en) IMMUNE IMAGE-MAKING AGENT FOR ANTIBODY-MEDICINE-CONJUGATE THERAPY
KR102508649B1 (ko) 사멸 수용체 작용제로 전신성 경화증 완화
WO2022214649A1 (fr) Nouvelles mutéines de lipocaline spécifiques au facteur de croissance des tissus conjonctifs (ctgf)
WO2025229980A1 (fr) Préparation lyophilisée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806595

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/07/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21806595

Country of ref document: EP

Kind code of ref document: A1